NCT02188082Unknown2 期
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 336
- 试验地点
- 12
- 主要终点
- Change From Baseline in Left Ventricular End Systolic Volume Index by ultrasound cardiogram
研究概览
简要总结
Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of IvabRadine hemisulfate Sustained-release Tablets versus placebo in patients with moderate to severe chronic systolic heart failure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •aged from 18 to 75 years, males or females
- •Willing to provide written informed consent
- •NYHA Class II, III, or IV for≥4 weeks, in stable clinical condition for
- •Optimized and unchanged chronic heart failure medications and dosages for≥4 weeks
- •Sinus rhythm with resting heart rate≥70 b.p.m.
- •Left-ventricular systolic dysfunction, with ejection fraction≥40% documented within previous 1 month
排除标准
- •Unstable cardiovascular condition(for example, hospital admission for worsening heart failure)
- •Recent (<2 months) myocardial infarction or recent or scheduled coronary revascularization
- •Stroke or transient cerebral ischaemia within previous 4 weeks
- •Severe primary valvular disease
- •Scheduled surgery of valvular heart disease
- •Active myocarditis
- •Congenital heart diseases
- •peripartum cardiomyopathy
- •hyperthyroid heart disease
- •On list for cardiac transplantation
- •Cardiac resynchronization therapy started within previous 6 months
- •Pacemaker with atrial or ventricular pacing (except biventricular pacing)˃40% of the time, or with stimulation threshold at the atrial or ventricular level˃60 b.p.m.
- •Permanent atrial fibrillation or flutter
- •Sick sinus syndrome, sinoatrial block, second and third degree atrio-ventricular block
- •History of symptomatic or sustained (≥30 s) ventricular arrhythmia unless a cardioverter/defibrillator implanted
- •Cardioverter/defibrillator shock within previous 6 months
- •Family history or congenital long QT syndrome or treated with selected QT-prolonging products(except amiodarone)
- •Contraindication or intolerance to ivabradine or lactulose
- •Severe or uncontrolled hypertension (SBP≥180 mmHg or DBP≥110 mmHg)
- •known anaemia(Hb<100 g/L)
- •Known moderate or severe liver disease(ALT/AST˃3ULN), known severe renal disease(Cr˃2ULN)
- •Pregnant or lactating women and women planning to become pregnant
- •Use of an investigational drug within 30 days of enrollment
- •Has a history of psychological illness/condition that interferes with ability to understand or complete requirements of the study
研究组 & 干预措施
IvabRadine hemisulfate Sustained-release Tablets
Experimental
5-15mg qd
干预措施: IvabRadine hemisulfate Sustained-release Tablets (Drug)
placebo
Placebo Comparator
5-15mg qd
干预措施: placebo (Drug)
结局指标
主要结局
Change From Baseline in Left Ventricular End Systolic Volume Index by ultrasound cardiogram
时间窗: baseline and week 32
次要结局
- Change From Baseline in Left Ventricular End Diastolic Volume Index and left ventricular ejection fraction(LVEF)(baseline and week 32)
- incidence of hospital admission for worsening heart failure、any cardiovascular hospital admission、 cardiovascular mortality、all-cause mortality(baseline and week 32)
- change from baseline in distance of 6-minute walking test(baseline and week 32)
- change from baseline in heart rate(baseline and week 32)
- change from baseline in scores of Kansas City Cardiomyopathy Questionnaire(baseline and week 32)
- change from baseline in NT-proBNP(baseline and week 32)
研究者
研究点 (12)
Loading locations...
相似试验
撤回
4 期
Ivabradine in Stage D Heart Failure Patients on Chronic InotropesHeart Failure NYHA Class IVNCT03631654University of Maryland, Baltimore
尚未招募
不适用
Role of Ivabradine in reducing tachycardia induced adverse outcomes in severe septic shockCTRI/2022/01/039557Calcutta national medical college
进行中（未招募）
不适用
Ivabradine IN IMPROVING THE EFFECTIVENESS OF THE ENDOTHELIAL FUNCTION IN PATIENTS WITH CAD undergoing coronary angioplastyEUCTR2012-005359-18-ITIVERSITA' CAMPUS BIOMEDICO
已完成
3 期
Ivabradine in controlling elevated heart rate among sick patientsCTRI/2010/091/002969Fluid Research Grant Christian Medical CollegeVellore Tamilnadu100
Unknown
1 期
Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart FailureDecompensated Heart FailureNCT02236247University of Sao Paulo50